Rossby Financial LCC Has $929,000 Position in Johnson & Johnson $JNJ

Rossby Financial LCC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,082 shares of the company’s stock after acquiring an additional 196 shares during the period. Rossby Financial LCC’s holdings in Johnson & Johnson were worth $929,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. GFG Capital LLC acquired a new position in Johnson & Johnson during the second quarter worth $35,000. Stone House Investment Management LLC acquired a new position in Johnson & Johnson during the first quarter worth $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson during the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson in the 1st quarter worth $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $190.31 on Tuesday. The firm has a market cap of $458.50 billion, a P/E ratio of 18.37, a PEG ratio of 2.24 and a beta of 0.40. The firm has a 50-day moving average of $182.54 and a 200 day moving average of $166.65. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent analyst reports. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research note on Wednesday, October 22nd. Stifel Nicolaus upped their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research note on Wednesday, October 15th. Finally, Bank of America upped their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $199.05.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.